Sheba ARC and Revealense launch AI-powered home neurology diagnostics

ARC, the global healthcare transformation engine and innovation arm of the Sheba Medical Center, has announced a collaboration with Revealense, creators of a neurological-AI engine for analysing behavioural DNA in video footage.

The collaboration establishes a joint venture focused on delivering an advanced neurological diagnostic solution.

The joint solution will deliver precise, clinically validated diagnoses across a wide range of neurological, cognitive and developmental conditions via a standard webcam in the comfort of a patient’s home.

 

Avner Halperin, CEO Sheba Impact at ARC, said: “The collaboration with Revealense exemplifies Sheba and ARC’s unique innovation model—which brings together clinicians on the ground, technological excellence, and robust infrastructure to establish entrepreneurial initiatives.

“This partnership will enable a faster neurological diagnostic process with increased accuracy and reliability, while improving accessibility by moving from the clinic to home.”

The first diagnostic protocols, led by Dr. Omer Bar Yosef, Director of the Child Development Center at Sheba Medical Center, will focus on autism, ADHD, and related conditions.

Beyond dramatically reducing the time needed for diagnosis, the venture also aims to enable earlier detection of syndromes, potentially allowing for initial assessments of autism and other conditions as early as 6 to 12 months of age.

The new integrated clinical and technological solution will allow diagnostic assessment to be conducted at home via standard webcam, aiming to create a more accessible and convenient process and enable more accurate data collection by allowing subjects to remain in their natural environment.

The behavioural analysis platform will assess an individual’s condition, factor in environmental influences, monitor changes over time, and recommend personalised, treatment-supporting care plans tailored to each user.

Additionally, the system will determine the subject’s baseline condition prior to the assessment process, addressing several shortcomings in current neurological diagnostics.

Dov Donin, Founder and CEO of Revealense, said: “With computational models, deep psychophysiological measurements, and real-time monitoring, we are at the forefront of a clinical revolution.

“It’s not just a new technology—it’s a paradigm shift that can improve and even save lives, while elevating the entire diagnostics landscape.

“We plan to accelerate development and regulatory processes in the coming months, with the goal of reaching the market in early 2026.”